Financial results for Quarter and Financial Year ended on 31 March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genomic Valley Biotech Ltd reported its audited standalone financial results for Q4 and FY25. Total revenue for FY25 jumped to ₹84.84 lakhs from ₹16.66 lakhs in FY24, a roughly 5x increase. Profit after tax surged to ₹35.61 lakhs (EPS ₹1.17) versus ₹1.52 lakhs (EPS ₹0.05) last year. However, Q4 FY25 alone posted a loss of ₹8.35 lakhs, reversing the strong full-year gains. The statutory auditor (Andros & Co.) issued an unmodified opinion. The company also appointed a new Independent Director, a new Secretarial Auditor (SBR & Co.), and reconstituted its board committees. The company's business operates in a single segment — Horticulture.
Full-year numbers show a sharp turnaround with strong revenue and profit growth, which is positive for shareholders. However, the Q4 loss and negative operating cash flow of ₹10.19 lakhs signal that the earnings quality and cash generation still need improvement.